Israel Englander 4 D Molecular Therapeutics, Inc. Transaction History

Millennium Management LLC

$224 Billion
Q1 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 11,444 shares of FDMT stock, worth $240,209. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,444

Holding current value

$240,209

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.03 - $35.87 $194,891 - $410,496	11,444 New	11,444 $364,000
Q2 2023 Aug 14, 2023	BUY	$15.16 - $23.26 $4.23 Million - $6.48 Million	278,701 New	278,701 $5.04 Million
Q4 2022 Feb 14, 2023	BUY	$6.85 - $25.46 $187,511 - $696,942	27,374 Added 10.52%	287,483 $6.39 Million
Q3 2022 Nov 14, 2022	SELL	$6.96 - $11.48 $99,660 - $164,382	-14,319 Reduced 5.22%	260,109 $2.09 Million
Q2 2022 Aug 15, 2022	BUY	$5.68 - $15.99 $1.12 Million - $3.16 Million	197,504 Added 256.75%	274,428 $1.92 Million

Q1 2022 May 16, 2022	BUY	$13.16 - $22.64 $1.01 Million - $1.74 Million	76,924 New	76,924 $1.16 Million
Q4 2021 Feb 14, 2022	SELL	$19.56 - $32.94 $3.04 Million - $5.11 Million	-155,258 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$22.73 - $36.04 $4.47 Million - $7.09 Million	-196,793 Reduced 55.9%	155,258 $4.19 Million
Q2 2021 Aug 16, 2021	BUY	$22.2 - $42.29 $397,424 - $757,075	17,902 Added 5.36%	352,051 $8.48 Million
Q1 2021 May 17, 2021	SELL	$35.94 - $52.67 $364,215 - $533,757	-10,134 Reduced 2.94%	334,149 $14.5 Million
Q4 2020 Feb 16, 2021	BUY	$38.43 - $47.36 $13.2 Million - $16.3 Million	344,283 New	344,283 $14.3 Million

Others Institutions Holding FDMT

# of Institutions

157

Shares Held

50.3M

Call Options Held

718K

Put Options Held

370K

View Full List

About 4D Molecular Therapeutics, Inc.

Ticker FDMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,382,400
Market Cap $680M
Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...

More about FDMT

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account